About the Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of injections pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands, mylife™ Diabetescare directly to patients or through pharmacies and clinics, and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs around 1 500 employees.

Ypsomed Diabetes Care

With mylife™ Diabetescare Ypsomed is successful in direct business with products and services for people with diabetes mellitus. Ypsomed is expanding into new markets worldwide with a networked portfolio. The objective is to further network the products and thus offer users real added value.

Ypsomed Delivery Systems

Ypsomed offers pharmaceutical and biotech customers injection systems and related services under the YDS brand, Ypsomed Delivery Systems. The platform approach allows Ypsomed to meet customer requirements without risks and in flexible production quantities. In future, the platform products will be supplemented by digital products.


In the 2018/19 financial year, our sales will be in the same order of magnitude as in financial year 2017/18. At the EBIT level, we expect an amount of between CHF 61 million and CHF 76 million for the 2018/19 financial year.

Key financial figures: multi-year overview

In thousand CHF 2017/18 2016/17 2015/16 2014/15
Sales of goods and services 466119 389 555 336 922 306 632
Gross Profit 139825 125 478 103 187 85 850
Operating Profit 61070 55 298 44 435 28 546
Net Profit 52060 46 247 35 812 19 395
EBITDA1 95539 87 763 73 270 57 369
Cash flow from operating activities 53269 75 064 76 687 41 381
Year-end headcount 1451 1 314 1 166 1 050

1 Operating profit before depreciation and Amortisation.